Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$118.79 USD

118.79
529,903

+0.29 (0.25%)

Updated Sep 4, 2024 12:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study

by Zacks Equity Research

Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.

Glaxo (GSK) Shares Continue to Witness Upside: Here's Why

by Zacks Equity Research

Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.

    Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta

    by Zacks Equity Research

    Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.

    Ekta Bagri headshot

    3 Biotech Stocks Likely to Maintain Solid Momentum in 2020

    by Ekta Bagri

    With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

    Epizyme (EPZM) Shares Soar on Lead Candidate's Progress

    by Zacks Equity Research

    Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies

    Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance

    by Zacks Equity Research

    Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.

    Sweta Killa headshot

    Biotech Leading in Q4: Best ETFs & Stocks

    by Sweta Killa

    We highlight five biotech ETFs and stocks that are leading the market in Q4.

    Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy

    by Zacks Equity Research

    Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

    Kinjel Shah headshot

    Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs

    by Kinjel Shah

    Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.

    AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU

    by Zacks Equity Research

    AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.

    Novartis' Asthma Candidate Fails in LUSTER Phase III Studies

    by Zacks Equity Research

    Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.

    Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu

    by Zacks Equity Research

    Novartis (NVS) obtains positive CHMP opinion for its wet AMD drug Beovu. A potential approval will boost its ophthalmology franchise.

    Novartis (NVS) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    Novartis (NVS) closed the most recent trading day at $93.06, moving +0.02% from the previous trading session.

    The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America

    Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy

    by Zacks Equity Research

    Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.

    Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA

    by Zacks Equity Research

    The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.

    Mark Vickery headshot

    Top Research Reports for Novartis, AbbVie & Sanofi

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), AbbVie (ABBV) and Sanofi (SNY).

    Neena Mishra headshot

    Why Biotech ETFs are Surging to New Highs

    by Neena Mishra

    increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

    Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research

    by Zacks Equity Research

    Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.

    Gilead (GILD) Announces Positive Long-Term Data on Yescarta

    by Zacks Equity Research

    Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.

    Biogen Up on New Data on Alzheimer's Candidate Aducanumab

    by Zacks Equity Research

    Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.

    Regeneron Reports Positive Data on Rare Blood Disorder Drug

    by Zacks Equity Research

    Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.

    Novartis (NVS) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    Novartis (NVS) closed at $91.64 in the latest trading session, marking a +0.09% move from the prior day.

    Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

    by Zacks Equity Research

    Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

    Biogen's Shares Down on Rating Downgrade by Baird Analyst

    by Zacks Equity Research

    Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.